Blood Utilization and Transfusion Reactions in Pediatric Patients Transfused with Conventional or Pathogen Reduced Platelets - 23/05/19
Abstract |
Objectives |
To assess the safety and efficacy of a Food and Drug Administration-approved pathogen-reduced platelet (PLT) product in children, as ongoing questions regarding their use in this population remain.
Study design |
We report findings from a quality assurance review of PLT utilization, associated red blood cell transfusion trends, and short-term safety of conventional vs pathogen-reduced PLTs over a 21-month period while transitioning from conventional to pathogen-reduced PLTs at a large, tertiary care hospital. We assessed utilization in neonatal intensive care unit (NICU) patients, infants 0-1 year not in the NICU, and children age 1-18 years (PED).
Results |
In the 48 hours after an index conventional or pathogen-reduced platelet transfusion, respectively, NICU patients received 1.0 ± 1.4 (n = 91 transfusions) compared with 1.2 ± 1.3 (n = 145) additional platelet doses (P = .29); infants 0-1 year not in the NICU received 2.8 ± 3.0 (n = 125) vs 2.6 ± 2.6 (n = 254) additional platelet doses (P = .57); and PEDs received 0.9 ± 1.6 (n = 644) vs 1.4 ± 2.2 (n = 673) additional doses (P < .001). Time to subsequent transfusion and red cell utilization were similar in every group (P > .05). The number and type of transfusion reactions did not significantly vary based on PLT type and no rashes were reported in NICU patients receiving phototherapy and pathogen-reduced PLTs.
Conclusions |
Conventional and pathogen-reduced PLTs had similar utilization patterns in our pediatric populations. A small, but statistically significant, increase in transfusions was noted following pathogen-reduced PLT transfusion in PED patients, but not in other groups. Red cell utilization and transfusion reactions were similar for both products in all age groups.
Le texte complet de cet article est disponible en PDF.Keywords : pathogen reduction, pediatric transfusion, transfusion safety
Abbreviations : CCI, INF, NICU, PED, PLT, UV
Plan
| E.S. receives research funding from Cerus Corporation as principal investigator for the phase IV Pathogen-Reduced Platelet Post Marketing Study (PIPER) and Pathogen-Reduced RBC Phase III Clinical Trial (ReCePI), and no personal remuneration received. E.G. receives research funding from Cerus Corporation as Co-investigator for the Phase IV Pathogen-Reduced Platelet Post Marketing Study (PIPER); from Terumo BCT as principal investigator of the Phase III MIPLATE study; and from Grifols Diagnostics for educational programming and participation on an Immunohematology Advisory Board. W.S. is a consultant for Hugo Health, a personal health record platform. The study sponsor had no role in data entry, analysis or manuscript preparation or review. The other authors declare no conflicts of interest. |
Vol 209
P. 220-225 - juin 2019 Retour au numéro
Article précédent
- Anti-Factor Xa–Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort
- Surbhi Saini, Ashley N. Folta, Katherine L. Harsh, Joseph R. Stanek, Amy L. Dunn, Sarah H. O'Brien, Riten Kumar
- Benefits of Physical Activity for Depression and Fatigue in Multiple Sclerosis: A Longitudinal Analysis
- Samantha Stephens, Shahriar Shams, Joshua Lee, Stephanie A. Grover, Giulia Longoni, Tara Berenbaum, Marcia Finlayson, Robert W. Motl, E. Ann Yeh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?